Miriam W. Lagemaat1, Eline K. Vos1, Marnix C. Maas1, Thiele Kobus1, Andreas K. Bitz2, 3, Mark J. van Uden1, Stephan Orzada2, 3, Arend Heerschap1, Tom W.J. Scheenen1, 2
1Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 2Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany; 3Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany
The potential of 31P MRSI to detect prostate cancer in vivo at 7T was investigated in 12 patients with or suspected of having prostate cancer. The metabolites ratios PE/γATP, PE/tPLM and Pi/yATP showed significant difference between prostate cancer and normal prostate tissue. The performance of 31P MRSI to detect prostate cancer may improve further by increases in spatial resolution.